Drugs / Beta-Caryophyllene
Beta-Caryophyllene
also known as
BCP · (-)-(e)-caryophyllene · (-)-trans-caryophyllene · Beta-caryophylene · Caryophyllene · FEMA NO. 2252 · NSC-11906 · Trans-.beta.-caryophyllene
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06218407 | Apr → Sep 2023 | chronic pain syndrome | Evon Medics LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04794205 | Sep 2021 → Apr 2022 | — | Hartford Hospital | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06671132 | Oct 2024 → Nov 2025 overdue | chronic pain syndrome | Evon Medics LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT04091789 | Sep 2019 → Mar 2020 | dysmenorrhea, migraine disorder, mood disorder | Pure Green | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04451863 Comparator | Dec 2021 → Nov 2025 overdue | substance abuse | University of California, Los Angeles | Active not recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Betacaryophyllene | “Betacaryophyllene (BCP) may be a possible candidate because it is isolatable, has shown evidence as a potential analgesic in preclinical research, is known to be safe for human...” NCT04794205 ↗5“A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗ “CBOT device with beta-caryophyllene” NCT06671132 ↗ |
| Known as | (-)-(e)-caryophyllene | ChEMBL registry synonym — accepted as the source's own label CHEMBL445740 ↗ |
| Known as | (-)-trans-caryophyllene | ChEMBL registry synonym — accepted as the source's own label CHEMBL445740 ↗ |
| Known as | BCP | “Betacaryophyllene (BCP) may be a possible candidate because it is isolatable, has shown evidence as a potential analgesic in preclinical research, is known to be safe for human...” NCT04794205 ↗2“CBOT plus (CBOT + beta caryophyllene [BCP])” NCT06218407 ↗ “CBOT-P [CBOT + beta caryophyllene (BCP)]” NCT06671132 ↗ |
| Known as | Beta-caryophylene | ChEMBL registry synonym — accepted as the source's own label CHEMBL445740 ↗ |
| Known as | Caryophyllene | ChEMBL registry synonym — accepted as the source's own label CHEMBL445740 ↗ |
| Known as | FEMA NO. 2252 | ChEMBL registry synonym — accepted as the source's own label CHEMBL445740 ↗ |
| Known as | NSC-11906 | ChEMBL registry synonym — accepted as the source's own label CHEMBL445740 ↗ |
| Known as | Trans-.beta.-caryophyllene | ChEMBL registry synonym — accepted as the source's own label CHEMBL445740 ↗ |
| Modality | Small molecule | — CHEMBL445740 ↗ |
| Route | Other | “A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗ |